scispace - formally typeset
D

Drakoulis Yannoukakos

Researcher at Aristotle University of Thessaloniki

Publications -  159
Citations -  12099

Drakoulis Yannoukakos is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 151 publications receiving 10048 citations. Previous affiliations of Drakoulis Yannoukakos include American Cancer Society & Institute of Cancer Research.

Papers
More filters
Journal ArticleDOI

RAD51B in Familial Breast Cancer

Liisa M. Pelttari, +115 more
- 05 May 2016 - 
TL;DR: It is suggested that loss-of-function mutations in RAD 51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.
Journal ArticleDOI

MicroRNA related polymorphisms and breast cancer risk

Sofia Khan, +161 more
- 12 Nov 2014 - 
TL;DR: Five miRNA binding site SNPs associated significantly with breast cancer risk are located in the 3′ UTR of CASP8, HDDC3, DROSHA, MUSTN1, and MYCL1, respectively, which belongs to miRNA machinery genes and has a central role in initial miRNA processing.
Journal ArticleDOI

Breast-Cancer Risk in Families with Mutations in PALB2

TL;DR: The data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA1 mutation carriers, and loss-of-function mutations in PALB1 are an important cause of hereditary breast cancer.
Journal ArticleDOI

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Nasim Mavaddat, +310 more
TL;DR: This PRS, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset is developed and empirically validated and is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.
Journal ArticleDOI

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

TL;DR: Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCa2.